Risk adjusted premium subsidies and risk sharing: key elements of the competitive sickness fund market in the Netherlands
- PMID: 12818745
- DOI: 10.1016/s0168-8510(02)00116-1
Risk adjusted premium subsidies and risk sharing: key elements of the competitive sickness fund market in the Netherlands
Abstract
As part of a market-oriented health care reform, in 1991 risk adjusted premium subsidies were introduced in the Dutch social health insurance sector. Currently the premium subsidies are primarily based on demographic variables. To mitigate the obvious inadequacy of these risk adjusters, the system of risk adjustment is supplemented with a system of risk sharing. This paper describes the main characteristics of the Dutch health care system and the development of risk adjustment and risk sharing in the last decade. The effects of introducing financial risk for Dutch sickness funds on risk selection and consumer mobility are analysed. The paper concludes with a description of expected future developments.
Similar articles
-
Risk adjustment in Switzerland.Health Policy. 2003 Jul;65(1):63-74. doi: 10.1016/s0168-8510(02)00117-3. Health Policy. 2003. PMID: 12818746
-
Risk adjustment and risk selection on the sickness fund insurance market in five European countries.Health Policy. 2003 Jul;65(1):75-98. doi: 10.1016/s0168-8510(02)00118-5. Health Policy. 2003. PMID: 12818747
-
Risk adjustment and risk sharing: the Israeli experience.Health Policy. 2003 Jul;65(1):37-48. doi: 10.1016/s0168-8510(02)00115-x. Health Policy. 2003. PMID: 12818744
-
Growing importance of capitation in Switzerland.Health Care Manag Sci. 2000 Feb;3(2):111-9. doi: 10.1023/a:1019081021645. Health Care Manag Sci. 2000. PMID: 10780279 Review.
-
How can we prevent cream skimming in a competitive health insurance market? The great challenge for the 90's.Dev Health Econ Public Policy. 1992;1:23-46. doi: 10.1007/978-94-011-2392-1_2. Dev Health Econ Public Policy. 1992. PMID: 10151748 Review. No abstract available.
Cited by
-
The impact of healthcare reform in the Netherlands.Pharmacoeconomics. 2004;22(2 Suppl 2):65-71. doi: 10.2165/00019053-200422002-00007. Pharmacoeconomics. 2004. PMID: 15660478 Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials